Valuation: SCYNEXIS, Inc.

Market Cap 38.23M 33.52M 30.9M 28.93M 54.24M 3.61B 55.37M 371M 144M 1.78B 144M 140M 6.18B P/E 2026 *
-0.94x
P/E 2027 * -1.53x
Enterprise Value 38.23M 33.52M 30.9M 28.93M 54.24M 3.61B 55.37M 371M 144M 1.78B 144M 140M 6.18B EV / Sales 2026 *
33.1x
EV / Sales 2027 * 5.73x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+1.05%
1 week-4.94%
Current month-31.74%
1 month-31.34%
3 months-40.80%
6 months-18.03%
Current year-23.90%
1 week 3.68
Extreme 3.68
4.02
1 month 3.68
Extreme 3.68
6.03
Current year 3.68
Extreme 3.68
9.12
1 year 3.68
Extreme 3.68
10.48
3 years 3.68
Extreme 3.68
30.96
5 years 3.68
Extreme 3.68
65.71
10 years 3.68
Extreme 3.68
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
01/04Buy

Chief Executive Officer

217,390 0.2736%
29/01Free

Chief Financial Officer

129,833 0.3094%
29/01Free

Chief Executive Officer

391,333 0.9325%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%-4.94%-30.38%-82.63% 38.23M
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.49%+6.71%+24.85%+40.83% 361.61B
Weighted average by Cap. +3.85%+8.93%+41.75%+80.17%

Financials

2026 *2027 *
Net sales 1.15M 1.01M 933K 873K 1.64M 109M 1.67M 11.21M 4.34M 53.8M 4.33M 4.24M 187M 6.68M 5.85M 5.4M 5.05M 9.47M 630M 9.67M 64.86M 25.1M 311M 25.07M 24.53M 1.08B
Net income -41.07M -36.01M -33.2M -31.08M -58.28M -3.87B -59.49M -399M -154M -1.91B -154M -151M -6.64B -28.73M -25.19M -23.22M -21.74M -40.76M -2.71B -41.61M -279M -108M -1.34B -108M -106M -4.64B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
26/06/26 USD 3.850 +1.05% 49,109
25/06/26 USD 3.810 -1.55% 47,373
24/06/26 USD 3.870 +1.31% 28,667
23/06/26 USD 3.820 +0.53% 76,803
22/06/26 USD 3.800 -6.17% 118,391
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.850USD
Average target price
33.55USD
Spread / Average Target
+771.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock